| 3.8765 -0.044 (-1.11%) | 09-14 14:45 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.88 | 1-year : | 5.21 |
| Resists | First : | 4.18 | Second : | 4.46 |
| Pivot price | 3.95  |
|||
| Supports | First : | 3.72 | Second : | 3.09 |
| MAs | MA(5) : | 3.91 |
MA(20) : | 4.01 |
| MA(100) : | 3.82 |
MA(250) : | 3.96 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.7 |
D(3) : | 32.1 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 6.42 | Low : | 2.71 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LRMR ] has closed above bottom band by 34.1%. Bollinger Bands are 42.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.07 - 4.09 | 4.09 - 4.11 |
| Low: | 3.8 - 3.82 | 3.82 - 3.84 |
| Close: | 3.89 - 3.92 | 3.92 - 3.95 |
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Thu, 10 Sep 2026
LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Tue, 04 Aug 2026
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update - GlobeNewswire
Thu, 23 Jul 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - PR Newswire
Wed, 15 Jul 2026
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy - Yahoo Finance
Fri, 03 Jul 2026
Here’s What Citi Thinks About Larimar Therapeutics (LRMR) - Yahoo Finance
Tue, 30 Jun 2026
Larimar Therapeutics: Late-Stage FA Program Advances Amid Execution Risks (NASDAQ:LRMR) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 104 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 93.4 (%) |
| Shares Short | 13,440 (K) |
| Shares Short P.Month | 11,300 (K) |
| EPS | -2.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.22 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -71 % |
| Return on Equity (ttm) | -139.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -156 (M) |
| Levered Free Cash Flow | -94 (M) |
| PE Ratio | -1.94 |
| PEG Ratio | 0 |
| Price to Book value | 3.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|